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S U M M A R Y
Objectives: The aim of this study was to identify the genetic relatedness of multiple drug-resistant (MDR)
Acinetobacter baumannii clinical isolates recovered from a hospital in Los Angeles.
Methods: Twenty-one MDR A. baumannii isolates were collected and their antibiotic susceptibilities
determined according to Clinical and Laboratory Standards Institute guidelines. Genes coding for
antibiotic resistance were identiﬁed by PCR, and their identities were conﬁrmed by DNA sequencing.
Clonal relationships were studied by pulsed-ﬁeld gel electrophoresis (PFGE) and multilocus sequence
typing (MLST).
Results: MDR consistently correlated with the presence of oxacillinases, mostly in the form of the
plasmid-mediated OXA-23 enzyme, which was detected in 12 (57.1%) isolates. GES-type carbapene-
mases were found in 20 (95.2%) strains, AAC in all 21 (100%) strains, and PER in seven (33.3%) strains, and
ISAba1 was detected in 16 (76.2%) isolates. The association between ISAba1 and resistance genes
conﬁrms insertion elements as a source of b-lactamase production. Of the 21 clinical isolates, ﬁve were
found to be related to sequence type 1 (ST1) and 16 to ST2, as analyzed by MLST. PFGE demonstrated that
the majority of clinical isolates were highly related (>85%).
Conclusions: This study supports a more complete understanding of genotyping of antibiotic resistance
for better assessment of MDR strain transmission.
 2015 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Acinetobacter baumannii has emerged as a predominant cause of
healthcare-associated infection (including infections seen in
wounded soldiers) in the USA and worldwide.1–10 A. baumannii
infections include pneumonia (especially ventilator-associated
pneumonia), wound infections, urinary tract infections, septice-
mia, and surgical site infections.11–13 Risk factors for A. baumannii
infections, especially in elderly individuals, include underlying
diseases (e.g. diabetes), immune suppression, burns, trauma,
invasive medical procedures, mechanical ventilation, catheters,
previous antibiotic treatment, and an extended hospital stay.14
Of great concern is the recent rise in the frequency of multiple
drug-resistant (MDR) and extremely drug resistant (XDR) A.* Corresponding author. Tel.: +1 310-222-6424; fax: +1 310-782-2016.
E-mail address: ibrahim@labiomed.org (A.S. Ibrahim).
http://dx.doi.org/10.1016/j.ijid.2015.10.016
1201-9712/ 2015 Published by Elsevier Ltd on behalf of International Society for Infect
creativecommons.org/licenses/by-nc-nd/4.0/).baumannii infections.2,11,12 The percentage of A. baumannii
infections caused by MDR strains (deﬁned as resistance to one
or more agents in at least three antimicrobial categories) and XDR
strains (deﬁned as resistance to all available antibiotics except
colistin and tigecycline) increased from <4% in 2000 to 60–70% in
2010.14 Infections caused by MDR A. baumannii are associated with
longer hospitalization, greater healthcare costs, greater morbidity,
and >60% mortality for bloodstream infections, as compared to
drug-susceptible strains.15–18 XDR infections are treatable only
with second-line agents, such as tigecycline and colistin, which are
associated with clinical failure, the development of resistance, and
nephrotoxicity.16,19–28 Furthermore, pandrug-resistant infections
(PDR) are resistant to every US Food and Drug Administration
approved antibiotic, and are hence untreatable.
Because of the difﬁculty in treating MDR, XDR, and PDR A.
baumannii infections, the surveillance of A. baumannii isolates
represents the cornerstone of prevention and control of theseious Diseases. This is an open access article under the CC BY-NC-ND license (http://
Table 2
Gene primers used for PCR ampliﬁcation of antibiotic resistance genes in clinical
Acinetobacter baumannii isolates
Gene Amplicon
size
Tm 8C Primer sequence
OXA-58 599 bp 52 AAGTATTGGGGCTTGTGCTG (Forward)
CCCCTCTGCGCTCTACATAC (Reverse)
OXA-51 353 bp 52 TAATGCTTTGATCGGCCTTG (Forward)
TGGATTGCACTTCATCTTGG (Reverse)
OXA-24 246 bp 52 GGTTAGTTGGCCCCCTTAAA (Forward)
AGTTGAGCGAAAAGGGGATT(Reverse)
OXA-23 501 bp 52 GATCGGATTGGAGAACCAGA (Forward)
ATTCTGACCGCATTTCCAT(Reverse)
OXA-48 438 bp 62 GCGTGGTTAAGGATGAACAC (Forward)
CATCAAGTTCAACCCAACCG (Reverse)
CTXM 550 bp 60 CGCTTTGCGATGTGCAG (Forward)
ACCGCGATATCGTTGGT (Reverse)
CTXM2 896 bp 55 CGGAATTCATGATGACTCAGAGCATTCG
(Forward)
GCTCTAGATTATTGCATCAGAAACCGTG
(Reverse)
PER 900 bp 43 ATGAATGTCATTATAAAAGC (Forward)
AATTTGGGCTTAGGGCAGAA (Reverse)
VEB 600 bp 55 CGACTTCCATTTCCCGATGC (Forward)
GGACTCTGCAACAAATACGC (Reverse)
QnrA 580 bp 54 AGAGGATTTCTCACGCCAGG (Forward)
TGCCAGGCACAGATCTTGAC (Reverse)
QnrS 428 bp 54 GCAAGTTCATTGAACAGGGT (Forward)
TCTAAACCGTCGAGTTCGGCG (Reverse)
QnrB 264 bp 54 GGMATHGAAATTCGCCACTG (Forward)
TTTGCYGYYCGCCAGTCGAA (Reverse)
TEM 850 bp 42 GAGTATTCAACATTTCCGTGTC (Forward)
TAATCAGTGAGGCACCTATCTC (Reverse)
GES 846 bp 55 ATGCGCTTCATTCACGCAC (Forward)
CTATTTGTCCGTGCTCAGGA (Reverse)
SHV 861 bp 55 ATGCGTTATWTTCGCCTGTGT (Forward)
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resistance mechanisms and determine the genetic relatedness of
clinical isolates recovered from Harbor–UCLA Medical Center, Los
Angeles County.
2. Methods
2.1. Bacterial identiﬁcation
Twenty-four clinical strains of A. baumannii were obtained from
inpatients of Harbor–UCLA Medical Center (HUMC), of which
21 isolates were investigated and identiﬁed to the species level
using Vitek 2 (BioMe´rieux Vitek Systems Inc., USA) and MicroScan
(WalkAway System, Siemens, USA) systems and biochemical
methods.
2.2. Antimicrobial susceptibility testing
Antimicrobial susceptibility testing was done for all HUMC
strains of A. baumannii by automated broth microdilution method
(Vitek 2) (Vitek AMS; BioMe´rieux Vitek Systems Inc., USA) and the
results were analyzed and interpreted according to the recom-
mended clinical breakpoints given in the Clinical and Laboratory
Standards Institute (CLSI) guidelines.29 The antibiotics tested were
amikacin, amoxicillin/clavulanic acid, ampicillin/sulbactam, am-
picillin, cefazolin, cefepime, cefotaxime, ceftazidime, ceftriaxone,
cefuroxime, cefoxitin, cefpodoxime, cephalothin, ceftriaxone,
ciproﬂoxacin, gentamicin, imipenem, meropenem, levoﬂoxacin,
nitrofurantoin, norﬂoxacin, tetracycline, tobramycin, trimetho-
prim/sulfamethoxazole, piperacillin/tazobactam, piperacillin, co-
listin, and tigecycline.
Extended-spectrum beta-lactamase (ESBL) production was
conﬁrmed by Vitek 2 analyzer, MicroScan, and disk diffusion
tests. Minimum inhibitory concentrations (MICs) of quinolones,
ﬂuoroquinolones, and b-lactams, including carbapenems, were
determined using the Etest method (CLSI 2012).29 Isolates that
showed resistance to at least three classes of antibiotics were
considered as MDR strains, whereas isolates showing resistance to
all antibiotics except for colistin and tigecycline were considered
as XDR strains.
2.3. Identiﬁcation of housekeeping genes
Bacterial DNA was extracted using a QIAquick PCR Puriﬁcation
Kit (Qiagen, USA). The primers used for the PCR ampliﬁcation of
seven housekeeping genes in A. baumannii are listed in Table 1.Table 1
Gene primers used for the detection of housekeeping genes by PCR in genes in
clinical Acinetobacter baumannii isolates in MLST studies
Gene Primer sequence Amplicon size
cpn60-F
cpn60-R
ACTGTACTTGCTCAAGC
TTCAGCGATGATAAGAAGTGG
405 bp
fusA-F
fusA-R
ATCGGTATTTCTGCKCACATYGAT
CCAACATACKYTGWACACCTTTGTT
633 bp
gltA-F
gltA-R
AATTTACAGTGGCACATTAGGTCCC
GCAGAGATACCAGCAGAGATACACG
483 bp
pyrG-F
pyrG-R
GGTGTTGTTTCATCACTAGGWAAAGG
ATAAATGGTAAAGAYTCGATRTCACCMA
297 bp
recA-F
recA-R
CCTGAATCTTCYGGTAAAAC
GTTTCTGGGCTGCCAAACATTAC
372 bp
rplB-F
rplB-R
GTAGAGCGTATTGAATACGATCCTAACC
CACCACCACCRTGYGGGTGATC
330 bp
rpoB-F
rpoB-R
GGTCCTGGTGGTTTAACACG
CGAATAACGATACGAGAAGCA
456 bp
MLST, multilocus sequence typing.2.4. Antibiotic resistance genes by PCR and DNA sequencing
The presence of resistance genes (Table 2) was investigated by
PCR using GoTaq Green Master Mix (Promega, USA). The PCR was
conducted in a GeneAmp 9700 system (Perkin-Elmer, IL, USA)
using the conditions speciﬁed for each primer as corresponding to
the reference source. PCR was performed for metallo-b-lactamase
and ESBL-encoding genes, including bla SIM (Seoul imipenemase),
bla VIM (Verona integron-encoded metallo-b-lactamases), bla VEB
(Vietnamese extended-spectrum-b-lactamase) and bla IMP (imi-
penemase), bla TEM-1 (Temoneira) and bla SHV (sulfhydryl
variable), bla CTX-M-like (cefotaximase-Munchen),30 bla NDM-1
(New-Delhi metallo-b-lactamase),31 qnrA, qnrB, and qnrS (quino-
lone resistance genes),32 aac (N-acetyltransferase),33 gyrA (DNA
gyrase subunit A) and parC (topoisomerase IV subunit C),34 AmpCTTAGCGTTGCCAGTGCTCG (Reverse)
CTX 554 bp 60 TCTTCCAGAATAAGGAATCCC (Forward)
CCGTTTCCGCTATTACAAAC (Reverse)
GyrA6 620 bp 56 CGACCTTGCGAGAGAAAT (Forward)
GTTCCATCAGCCCTTCAA (Reverse)
ParCF43 964 bp 53 AGCGCCTTGCGTACATGAAT (Forward)
GTGGTAGCGAAGAGGTGGTT (Reverse)
AAC 482 bp 55 TTGCGATGCTCTATGAGTGGCTA (Forward)
CTCGAATGCCTGGCGTGTTT (Reverse)
SIM 570 bp 65 TACAAGGGATTCGGCATCG (Forward)
TAATGGCCTGTTCCCATGTG (Reverse)
IMP 232 bp 60 GGAATAGAGTGGCTTAAYTC (Forward)
TCGGTTTAAYAAAACAACCACC (Reverse)
VIM 390 bp 62 GATGGTGTTTGGTCGCATA (Forward)
CGAATGCGCAGCACCAG (Reverse)
NDM 621 bp 65 GGTTTGGCGATCTGGTTTTC (Forward)
CGGAATGGCTCATCACGATC (Reverse)
KPC 798 bp 58 CGTCTAGTTCTGCTGTCTTG (Forward)
CTTGTCATCCTTGTTAGGCG (Reverse)
IS 615 bp 56 GTGCCCAAGGGGAGTGTATG (Forward)
ACYTTACTGGTRCTGCACAT (Reverse)
ISAbaI 389 bp 57 ATGCAGCGCTTCTTTGCAGG (Forward)
AATGATTGGTGACAATGAAG (Reverse)
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tance),36 bla GES (Guiana extended spectrum),36 OXA-(oxacilli-
nase)-encoding genes including bla OXA-51-like, bla OXA-58-like,
bla OXA-48-like, bla OXA-23-like, bla OXA-24-like,37,38 IS (inser-
tion sequence),39 and ISAba1.40 Ampliﬁed PCR products were
puriﬁed with a Qiagen puriﬁcation kit (Qiagen, USA) according to
the manufacturer’s instructions, and both strands were sequenced
by automated ABI 3100 DNA sequencer (Applied Biosystems). The
BLAST program of the National Center for Biotechnology Informa-
tion (http://www.ncbi.nlm.nih.gov) was used to search and
compare databases for similar nucleotide acid sequences.
2.5. Pulsed-ﬁeld gel electrophoresis (PFGE)
PFGE analysis was based on techniques described elsewhere.41
PFGE of ApaI-digested genomic DNA (Promega, UK) from each
HUMC strain was performed to detect the relationships among the
clinical isolates of A. baumannii. After PFGE, the gels were stained
with ethidium bromide and scanned. The analysis of gels was
performed using BioNumerics software version 7.1 (Applied Maths,
Ghent, Belgium). This software facilitates the development of the
algorithms necessary for the comparison of proﬁles of isolates
based on the Dice coefﬁcient and the hierarchical unweighted pair
arithmetic average algorithm. Cluster analysis and phylogenetic
trees were subsequently analyzed with an optimization of 1.0% and
a tolerance of 0.7%. Isolates were considered to belong to the same
PFGE clone if their Dice similarity index was 85%.
2.6. Multilocus sequence typing (MLST)
MLST was based on a sequence analysis of the internal
fragments of seven housekeeping genes: cpn60 (60-kDa chaper-
onin), fusA (elongation factor EF-G), gltA (citrate synthase), pyrG
(CTP synthase), recA (homologous recombination factor), rplB (50S
ribosomal protein L2), and rpoB (RNA polymerase subunit B). The
MLST scheme including ampliﬁcation and sequencing primers,
allele sequences, and sequence types (STs) are available at the
Pasteur Institute MLST website (http://www.pasteur.fr/recherche/
genopole/PF8/mlst/references_Abaumannii.html). The housekeep-
ing genes for the MLST scheme were selected on the basis of their
sequence availability in GenBank and prior studies of the
phylogenetic relationships for the genus Acinetobacter and their
presence in other MLST schemes available for other bacterial
species. PCR primers were chosen from previous studies or were
designed for ampliﬁcation of the seven selected genes (Table 1).
All PCR ampliﬁcations were carried out using GoTaq Green
Master Mix (Promega, USA) under the following conditions:
35 cycles (denaturation at 94 8C for 30 s, annealing at 50 8C for 30 s,
and extension at 72 8C for 30 s) proceeded by a 2-min denaturation
at 94 8C and followed by a 5 min extension at 72 8C. PCR products
were directly puriﬁed from the reaction mixture with the QIAquick
PCR Puriﬁcation Kit (Qiagen GmbH, Hilden, Germany) according to
the manufacturer’s recommendations. Sequencing of internal DNA
fragments of 297 bp to 633 bp of the selected housekeeping genes
was performed using an ABI Prism 377 sequencer using the ABI
Prism BigDye Terminator Cycle Sequencing Ready Reaction Kit
v.3.1 (PE Applied Biosystems, Foster City, CA) in accordance with
the manufacturer’s recommendations. PCR primers were used for
sequencing on both strands. Sequence data were aligned using
ClustalW (http://www.ebi.ac.uk/Tools/msa/clustalw2/).
2.7. Plasmid curing experiments
The plasmid curing procedure was performed for ﬁve selected
HUMC isolates (HUMC-1, HUMC-3, HUMC-4, HUMC-10, and
HUMC-19) of A. baumannii using 47 8C as a growing temperature.The ﬁve isolates were selected to represent the presence or absence
of resistance genes and ISAba1. Plasmid curing using temperature
as a curing agent was examined after 3 days of incubation at 47 8C,
followed by antibiotic sensitivity testing.
3. Results
3.1. Susceptibility of A. baumannii isolates to antimicrobials
A total of 21 clinical samples were analyzed in 2011. The
sources of the isolates included nine respiratory secretion samples
(42.9%), four sputum samples (19%), two abdominal secretion
samples (9.5%), two samples from wounds (9.5%), and one from
each of urine, bronchoalveolar lavage, foot, and groin samples
(each 4.8%).
Antibiotic sensitivity testing revealed that all of the isolates
were resistant to ceftriaxone, ceftazidime, cefotaxime, ciproﬂoxa-
cin, cefepime, gentamicin, levoﬂoxacin, tetracycline, and ticarcil-
lin/K clavulanate, whereas two isolates were found to be sensitive
to meropenem, eight to imipenem, three to amikacin, four to
ampicillin/sulbactam, and one each to trimethoprim/sulfameth-
oxazole and tobramycin. All clinical isolates of A. baumannii were
sensitive to colistin and tigecycline, with the exception of one and
two strains, respectively. Susceptibility testing results of the
clinical isolates studied are summarized in Table 3.
3.2. Characterization of carbapenemases and other b-lactamase
genes
The presence of oxacillinases, mostly in the form of the
plasmid-mediated OXA-23 enzyme, was detected in 12 (57.1%)
isolates, as well as b-lactamase resistance genes in seven isolates
harboring PER (33.3%), 21 isolates harboring AAC (100%), and
20 isolates harboring GES (95.2%)-type enzymes (Table 4). MDR
consistently correlated with the presence of oxacillinases, mostly
in the form of plasmid-mediated OXA-51 and OXA-23 enzymes,
which were detected in 21 (100%) and 13 (61.9%) of the clinical
isolates collected, respectively. None of the isolates harbored OXA-
58, OXA-24, or OXA-48. ISAba1 was detected in 16 (76.2%) isolates.
None of the clinical isolates harbored KPC, IMP, VIM, SIM, NDM, or
QNR-type genes (Table 4).
3.3. Frequency of insertion sequences for different enzymes
The frequency of insertion sequences in all of the clinical
isolates of A. baumannii harboring antibiotic resistance genes was
found to be 7/12 (58.3%) in OXA-23, 7/7 (100%) in PER, 15/20 (75%)
in GES, and 17/21 (81%) in AAC (Table 4).
3.4. Molecular genotyping of A. baumannii clinical isolates
Genotyping analysis of the 21 clinical isolates by PFGE revealed
the circulation of different PFGE types. A high clonal relationship
was found among all the strains typed. All the isolates were MDR to
at least three antimicrobial groups. PFGE analysis demonstrated
that the majority of clinical isolates were highly related (85%).
MLST studies showed that ﬁve (23.8%) clinical isolates of A.
baumannii were related to sequence type 1 (ST1) and 16 (76.2%) to
sequence type 2 (ST2) (Table 5). The results of PFGE and MLST are
summarized in Figure 1, along with information on the original
sources of the specimens.
3.5. Plasmid curing of A. baumannii clinical isolates
The results showed that the ﬁve clinical isolates cured for
plasmids did not lose their ability for resistance to antimicrobial
Table 3
Susceptibility proﬁles of Harbor–UCLA Medical Center strainsa
Antibioticb
Isolate A/S AK CAZ CP CPE GM IMP LVX MER T/S TE TIM TO CST TGC
HUMC-1 I
(16/8)
S
(16)
R
(>32)
R
(>2)
R
(>16)
R
(>8)
R
(>8)
R
(>4)
R
(>8)
R
(>2/38)
I
(8)
R
(>64)
R
(>8)
S
(2)
S
(1)
HUMC-3 R
(>16/8)
R
(>32)
R
(>16)
R
(>2)
R
(>16)
R
(>8)
R
(>8)
R
(>4)
R
(>8)
R
(>2/38)
I
(8)
R
(>64)
R
(>8)
S
(2)
R
(4)
HUMC-4 I
(16/8)
S
(16)
R
(>16)
R
(>2)
R
(>16)
R
(>8)
R
(>8)
R
(>4)
R
(>8)
R
(>2/38)
I
(8)
R
(>64)
S
(4)
S
(2)
I
(2)
HUMC-5 R
(>16/8)
R
(>32)
R
(>16)
R
(>2)
R
(>16)
R
(>8)
S
(4)
R
(>4)
I
(8)
R
(>2/38)
R
(>8)
R
(>64)
R
(>8)
S
(2)
S
(1)
HUMC-6 R
(>16/8)
R
(>32)
R
(>16)
R
(>2)
R
(>16)
R
(>8)
S
(4)
R
(>4)
I
(8)
R
(>2/38)
R
(>8)
R
(>64)
R
(>8)
S
(2)
S
(1)
HUMC-9 S
(8/4)
S
(16)
R
(>16)
R
(>2)
R
(>16)
R
(>8)
I
(8)
R
(>4)
R
(>8)
R
(>2/38)
I
(8)
R
(>64)
R
(>8)
S
(2)
I
(2)
HUMC-10 S
(8/4)
R
(>32)
R
(>16)
R
(>2)
R
(>16)
R
(>8)
S
(4)
R
(>4)
S
(4)
R
(>2/38)
R
(>8)
R
(>64)
R
(>8)
S
(2)
S
(1)
HUMC-11 R
(>16/8)
R
(>32)
R
(>16)
R
(>2)
I
(16)
R
(>8)
S
(4)
R
(>4)
I
(8)
R
(>2/38)
R
(>8)
R
(>64)
R
(>8)
S
(2)
S
(1)
HUMC-12 R
(>16/8)
R
(>32)
R
(>16)
R
(>2)
R
(>16)
R
(>8)
S
(4)
R
(>4)
S
(4)
R
(>2/38)
R
(>8)
R
(>64)
R
(>8)
S
(2)
S
(1)
HUMC-13 R
(>16/8)
R
(>32)
R
(>16)
R
(>2)
R
(>16)
R
(>8)
S
(4)
R
(>4)
I
(8)
R
(>2/38)
R
(>8)
R
(>64)
R
(>8)
S
(2)
S
(1)
HUMC-14 R
(>16/8)
R
(>32)
R
(>16)
R
(>2)
R
(>16)
R
(>8)
S
(4)
R
(>4)
I
(8)
R
(>2/38)
R
(>8)
R
(>64)
R
(>8)
S
(2)
S
(1)
HUMC-15 I
(16/8)
R
(>32)
R
(>16)
R
(>2)
R
(>16)
R
(>8)
R
(>8)
R
(>4)
R
(>8)
R
(>2/38)
I
(8)
R
(>64)
R
(>8)
S
(2)
R
(4)
HUMC-16 I
(16/8)
R
(>32)
R
(>16)
R
(>2)
R
(>16)
R
(>8)
R
(>8)
R
(>4)
R
(>8)
S
(2/38)
I
(8)
R
(>64)
R
(>8)
S
(2)
S
(1)
HUMC-17 I
(16/8)
R
(>32)
R
(>16)
R
(>2)
R
(>16)
R
(>8)
R
(>8)
R
(>4)
R
(>8)
R
(>2/38)
R
(>8)
R
(>64)
R
(>8)
S
(2)
S
(1)
HUMC-18 I
(16/8)
R
(>32)
R
(>16)
R
(>2)
R
(>16)
R
(>8)
R
(>8)
R
(>4)
R
(>8)
R
(>2/38)
I
(8)
R
(>64)
R
(>8)
S
(2)
I
(2)
HUMC-19 S
(8/4)
R
(>32)
R
(>16)
R
(>2)
R
(>16)
R
(>8)
R
(>8)
R
(>4)
R
(>8)
R
(>2/38)
R
(>8)
R
(>64)
R
(>8)
S
(2)
S
(1)
HUMC-20 I
(16/8)
R
(>32)
R
(>16)
R
(>2)
R
(>16)
R
(>8)
R
(>8)
R
(>4)
R
(>8)
R
(>2/38)
R
(>8)
R
(>64)
R
(>8)
S
(2)
S
(1)
HUMC-21 I
(16/8)
R
(>32)
R
(>16)
R
(>2)
R
(>16)
R
(>8)
R
(>8)
R
(>4)
R
(>8)
R
(>2/38)
R
(>8)
R
(>64)
R
(>8)
R
(>2)
S
(1)
HUMC-22 I
(16/8)
R
(>32)
R
(>16)
R
(>2)
R
(>16)
R
(>8)
R
(>8)
R
(>4)
R
(>8)
R
(>2/38)
I
(8)
R
(>64)
R
(>8)
S
(2)
S
(1)
HUMC-23 S
(8/4)
R
(>32)
R
(>16)
R
(>2)
R
(>16)
R
(>8)
R
(>8)
R
(>4)
R
(>8)
R
(>2/38)
R
(>8)
R
(>64)
R
(>8)
S
(2)
S
(1)
HUMC-24 R
(>16/8)
R
(>32)
R
(>16)
R
(>2)
I
(16)
R
(>8)
S
(4)
R
(>4)
I
(8)
R
(>2/38)
R
(>8)
R
(>64)
R
(>8)
S
(2)
S
(1)
a Isolates were designated susceptible (S), intermediate (I), or resistant (R) according to Clinical and Laboratory Standards Institute antibiotic breakpoint guidelines.
Minimum inhibitory concentrations (MIC) are shown in brackets.
b A/S, ampicillin/sulbactam; AK, amikacin; CAZ, ceftazidime; CP, ciproﬂoxacin; CPE, cefepime; GM, gentamicin; IMP, imipenem; LVX, levoﬂoxacin; MER, meropenem; T/S,
trimethoprim/sulfamethoxazole; TE, tetracycline; TIM, ticarcillin/K clavulanate; TO, tobramycin; CST, colistin; TGC, tigecycline.
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even after 3 days of incubation at 47 8C (Supplementary Material,
Table S1).
4. Discussion
Antimicrobial resistance in Enterobacteriaceae has emerged as a
major clinical problem in recent years.42,43 Drug resistance in this
group of bacteria is mainly caused by the emergence and
proliferation of ESBLs,44 ﬂuoroquinolone resistance,45 and the
dissemination of MDR and carbapenem-resistant strains.46,47 Data
from the National Healthcare Safety Network at the US Centers for
Disease Control and Prevention (CDC) have shown high rates of
carbapenem resistance among A. baumannii throughout the USA,
with an increased incidence in hospital-associated infections,
especially ventilator-associated pneumonia, central line-associat-
ed bloodstream infections, catheter-associated urinary tract
infections, and surgical site infections.48 Understanding the
fundamental mechanisms that underline Acinetobacter infections,
including the original source of the infecting strains, resistance
patterns, and their clonality and geographical spread, is critical forthe development of appropriate infection control measures and
more efﬁcient treatment strategies.
Two typing methods were used in this study to detect the
molecular epidemiology of A. baumannii isolates from HUMC in Los
Angeles County: PFGE and MLST.49,50 Using MLST, it was found that
the clinical isolates of A. baumannii belonged to two main clones:
ST1 and ST2. The high clonal relationship in the PFGE analysis
between HUMC strains as reﬂected by 85% is in agreement with
the MLST studies that showed more than 76.2% of the tested
isolates to belong to ST2. It is prudent to mention that MLST is a
high-resolution molecular tool for discriminating between closely
related bacterial species.50 The ﬁrst MLST scheme for A. baumannii
was published by Bartual et al.51 and by Diancourt et al.52 at the
Pasteur Institute (http://www.pasteur.fr/recherche/genopole/PF8/
mlst/Abaumannii.html); this was used in the present study.
Furthermore, MLST approaches to the genotyping of A. baumannii
isolates that are based on sequencing regions of housekeeping
genes,53 are reproducible and portable, facilitating comparisons
among laboratories worldwide. While MLST is an expensive typing
method due to the need for DNA sequencing, selective use of this
technique can substantially enhance our understanding of
Table 4
Antibiotic resistance gene results detected by PCR in Harbor–UCLA Medical Center
clinical strainsa
Gene
Isolate OXA-51 OXA-23 PER GES AAC ISAba1
HUMC-1 + +  + + +
HUMC-3 + +  + + 
HUMC-4 +  + + + +
HUMC-5 +  + + + +
HUMC-6 +  + + + +
HUMC-9 + +  + + +
HUMC-10 +   + + +
HUMC-11 +  + + + +
HUMC-12 +   + + +
HUMC-13 +  + + + +
HUMC-14 +  + + + +
HUMC-15 + +  + + 
HUMC-16 + +  + + +
HUMC-17 + +  + + +
HUMC-18 + +  + + 
HUMC-19 + +   + +
HUMC-20 + +  + + +
HUMC-21 + +  + + 
HUMC-22 + +  + + 
HUMC-23 + +  + + +
HUMC-24 +  + + + +
a () denotes negative, (+) denotes positive PCR reaction.
Table 5
Allele and sequence number results of Harbor–UCLA Medical Center clinical isolates
as analyzed by MLST
HUMC strains Allele number ST
Cpn60 fusA gltA pyrG recA rplB rpoB
HUMC-1 2 2 2 2 2 2 2 2
HUMC-3 1 1 1 1 5 1 1 1
HUMC-4 2 2 2 2 2 2 2 2
HUMC-5 2 2 2 2 2 2 2 2
HUMC-6 2 2 2 2 2 2 2 2
HUMC-9 2 2 2 2 2 2 2 2
HUMC-10 2 2 2 2 2 2 2 2
HUMC-11 2 2 2 2 2 2 2 2
HUMC-12 2 2 2 2 2 2 2 2
HUMC-13 2 2 2 2 2 2 2 2
HUMC-14 2 2 2 2 2 2 2 2
HUMC-15 1 1 1 1 5 1 1 1
HUMC-16 1 1 1 1 5 1 1 1
HUMC-17 2 2 2 2 2 2 2 2
HUMC-18 1 1 1 1 5 1 1 1
HUMC-19 2 2 2 2 2 2 2 2
HUMC-20 2 2 2 2 2 2 2 2
HUMC-21 2 2 2 2 2 2 2 2
HUMC-22 1 1 1 1 5 1 1 1
HUMC-23 2 2 2 2 2 2 2 2
HUMC-24 2 2 2 2 2 2 2 2
MLST, multilocus sequence typing; ST, sequence type.
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locations. In contrast, although PFGE analysis is highly discrimi-
natory, it is not suitable for inter-laboratory comparisons unless
the procedures are meticulously standardized,49 and the interpre-
tation of the pulsed ﬁeld results may be a challenge in non-
outbreak situations.50 However, genotyping by methods like PFGE
allows the investigation of clonal spread and can be used to
identify the source of the original infection. Therefore, wheneverFigure 1. Dendrogram representing PFGE proﬁles, MLST results, and thpossible, the use of both methods for genotyping is advisable.
Equally important, our previous work using PFGE analysis on ﬁve
isolates of MDR A. baumannii demonstrated that all of these
isolates were genetically different from the drug-susceptible A.
baumannii ATCC 17978.54
Previous genome sequencing studies have shown that MDR A.
baumannii strains causing infection are related to one another with
extensive variations in gene content, even among strains that aree site of infection of Harbor–UCLA Medical Center clinical isolates.
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Several mechanisms contribute to this diversity, including the
transfer of mobile genetic elements and mobilization of insertion
sequences.55 In addition, widespread genetic variation among
clinical isolates from the same hospital and/or patient reinforces
the need for molecular diagnostic testing and genomic analysis to
determine resistance proﬁles, rather than to rely primarily on
strain typing and antimicrobial resistance phenotypes for molec-
ular epidemiological studies.55
The role of insertion sequences is important to understand the
expression of carbapenemases in A. baumannii (e.g., ISAba1). It has
been reported that insertion sequences play a role in the
expression of the carbapenem-hydrolyzing b-lactamases.40 In
this study, ISAba1 was detected in almost 76.2% of the clinical
isolates. It was also found that not all isolates harboring ISAba1
were resistant to carbapenems (Table 4). These ﬁndings are
concordant with the fact that resistance to carbapenems is mainly
caused by the OXA-type enzymes, including plasmid-encoded b-
lactamases (OXA-23, OXA-40, and OXA-58).38 Studies have shown
that chromosomally encoded OXA b-lactamase (OXA-51-like) can
confer resistance to carbapenems in A. baumannii when the genetic
environment around the gene promotes its expression.38,56 The
ﬁndings of the present study are in agreement with those of other
studies in which it has been shown that almost all A. baumannii
strains possess chromosomally encoded OXA b-lactamase (OXA-
51-like). The high frequency of insertion sequences for different
types of oxacillinases and carbapenemases could be due to
differences in antibiotic treatment among patients. The plasmid
curing studies showed that clinical strains did not lose their ability
for resistance to antimicrobial agents, indicating a high stability of
the acquired plasmids.
The two clonal lineages of MDR A. baumannii identiﬁed in this
study have been found in other US States as well.46 In the USA, an
outbreak of MDR A. baumannii in Houston was caused by clonal
complex 92 (an ST2 type).57 In addition, a survey of bacterial
isolates collected from 52 US hospitals over 6 years also showed
the preponderance of the same clone.58 Other studies have
revealed a good correlation between antibiotic susceptibility
proﬁles and genetic ﬁngerprints from clinical A. baumannii isolates
from nosocomial outbreaks and the mechanisms of antibiotic
resistance.59 Molecular epidemiology of clinical isolates of A.
baumannii identiﬁed in New York, Pennsylvania, Florida, Missouri,
Nevada, and California revealed the predominance of CC92 among
carbapenem non-susceptible isolates in US hospitals, suggesting
that they constitute part of the global epidemic driven by this
clonal complex belonging to EUII.46 Worldwide, it is not surprising
to detect common STs. For examples, ST1 and ST2 have been
identiﬁed previously in the Middle East including Saudi Arabia,
Lebanon, and Yemen.60–62 Moreover, ST1 and ST2 are known to be
endemic strains in European countries including Spain, Italy,
France, and Greece,63–66 Asia including Japan and Taiwan,67,68 and
even the Scandinavian countries like in Denmark.69
There is no doubt that early pathogen identiﬁcation, followed
by the right antibiotic treatment may reduce the prevalence of
antibiotic resistance in A. baumannii. Therefore, future studies will
focus on characterizing the composite transposable elements in
detail. Although the clinical isolates collected in this study may not
represent the overall epidemiology of MDR A. baumannii since all
originated from one hospital in Los Angeles County, it is planned to
further research the epidemiological analyses of this organism
beside other MDR and XDR organisms in other hospitals for
continuous surveillance of these strains in the USA.
In conclusion, two distinct clones of MDR or XDR A. baumannii
were identiﬁed at Harbor–UCLA Medical Center in Los Angeles
County. The epidemiological data obtained suggest that the
increase in the number of A. baumannii infections in that hospitalwas caused by these two clones. MLST studies may be more
accurate in distinguishing between A. baumannii isolates than
PFGE typing. This study supports a more complete understanding
of genotyping of antibiotic resistance for better assessment of MDR
and/or XDR strain transmission. Continuous surveillance is needed
to monitor the spread of these strains equipped with multiple drug
resistance mechanisms.
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